Copper
As of the edition of 20 October 2026, Copper is a small molecule: marketed, first approved in 1949 (CH); no US protection of its own is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- CU-7
- First approved
- 16 June 1949 (CH)
- Approvals on record
- 5 in 2 regions
- Holder of the most recent approval
- Sebela Womens Health; 4 holders in all
- Registered trials
- 7, 3 stopped early
- Disease areas
- Cancer; Urinary and reproductive; Immune system; Infections; Pregnancy and women's health; Skin and connective tissue
US protection
No US protection of its own is listed.
The FDA registers list no drug-substance patent or exclusivity of its own that counts for this drug.
Sebela Womens Health holds a later exclusivity on its own new formulation or combination product, ending 2028; it does not protect the original drug.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 1 | 1 | 0 | 0 | 1 |
| Phase 2 | 4 | 1 | 1 | 2 |
| Phase 3 | 1 | 1 | 0 | 0 |
| All trials | 7 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Population Council | Later holder | 1984 to now |
| Pfizer | Acquired holder | 2002 to now |
| CooperSurgical | Acquired holder | 2018 to now |
| Sebela Womens Health | Later holder | 2025 to now |